Corvidia Therapeutics to Participate in 38th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 8, 2020 /PRNewswire/ -- Corvidia Therapeutics Inc., a clinical stage company focused on the research, development and commercialization of transformative therapies in cardio-renal disease, today announced the company will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14 at 2:30 pm.
Details:
Location: Westin St. Francis Hotel, San Francisco, CA
Presentation Room: Elizabethan D
Date/Time: Tuesday, January 14 at 2:30pm PST
About Corvidia Therapeutics Inc.
Corvidia Therapeutics is a clinical stage company focused on the research, development and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for atherosclerotic cardiovascular disease (ASCVD) and inflammation in chronic kidney disease (CKD) patients, and high triglyceride-induced acute pancreatitis (AP). Founded in 2015, Corvidia Therapeutics is headquartered in Waltham, Massachusetts. Learn more at: www.corvidiatx.com.
Press Inquiries:
McDougall Communications on behalf of Corvidia Therapeutics Inc.
Elizabeth Harness, [email protected], Tel: +1 (585) 435-7379
Christopher Knospe, [email protected], Tel: +1 (716) 440-5580
SOURCE Corvidia Therapeutics Inc.
![](https://rt.prnewswire.com/rt.gif?NewsItemId=NY81732&Transmission_Id=202001080730PR_NEWS_USPR_____NY81732&DateId=20200108)
Share this article